Challenges and Progress in Immune Therapies for AML

The treatment landscape of acute myeloid and lymphoblastic leukemia continues to evolve with the addition of novel therapies and methods to monitor disease. One such example is the use of measurable residual disease (MRD) status to plan treatment, determine disease prognosis, and compare treatment efficacy. In terms of novel treatments, CAR T-cell therapy has proven promising for treating acute lymphoblastic leukemia, and will continue to be a key focus of research in the near future. In this podcast, Alan Burnett, MD, PhD, of Cardiff University, Cardiff, UK; Andrew Wei, MBBS, PhD, FRACP, FRCPA, of Monash University, Victoria, Australia; and Mark Levis, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discuss the future of acute leukemia therapy at the International Workshop on Acute Leukemias (iwAL) 2019 meeting held in Barcelona, Spain.

The post iwAL 2019: looking to the future of acute leukemia therapy appeared first on VJHemOnc.